|
 |
| home > epc > winter 2002 > prescription drug co-promotion: 21st century dealmaking |
|
|
 PUBLICATIONS |
European Pharmaceutical Contractor
|
The pharmaceutical industry has experienced a flurry of announced and, to a lesser extent, consummated mergers in the US and Western Europe in the past decade. Many of these business combinations appear to have been driven by a desire to access promising drug pipelines, consolidate research and development efforts, penetrate specific geographic markets for prescription drugs (often the US where foreign partners are involved) and rationalise regulatory and sales functions.
Often overlooked in this flurry of M&A activity however, is the growing trend among pharmaceutical companies, large and small, to achieve many of the benefits of 'traditional' business combinations by engaging in 'blockbuster' drug co-promotion activity where two life science companies collaborate in the marketing of very promising prescription drugs. In some of the recent, more complex co-promotions, co-operating companies pool their resources and strengths in conducting clinical trials, obtaining requisite regulatory and, for example in Western Europe, pricing, approvals and mass marketing and detailing the product.
For pharmaceutical companies, these types of co-promotion can result in significant revenue enhancement without the issues of post-deal integration and cost synergy management following strategic mergers. A number of pharmaceutical companies have supplemented strategic mergers with these types of co-promotions. For other companies who are developing potentially promising blockbuster drugs, co-promotion can offer upfront and milestone cash infusions, access to complimentary technology and, with the appropriate marketing partner, increased prospects for a successful drug launch.
|
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
4th Annual Patient Recruitment and Retention in Clinical Trials
13-15 October 2008, Amsterdam
Patient recruitment
is now consuming thirty percent of clinical trial time - more time than any
other clinical trial activity - and almost half of all trial delays result from
patient recruitment problems.
As the
recruiting culture becomes more sophisticated and the forces affecting patient
enrollment grow more numerous and complex, pharmaceutical companies are
striving to discover new strategies to facilitate enrollment in clinical
trials.
With
increasing industry pressure to develop, test and market greater numbers of new
drugs faster, pharmaceutical companies need to perform clinical trials as
quickly as possible. Inefficient patient recruitment processes is a formidable
barrier to pharmaceutical companies' success in launching new products.
Improving the patient recruitment process is imperative to avoid wasted
investments and eliminate costly delays in bringing new drugs to market --
today and even more so in the not-so-distant future. Improved patient
recruitment presents one of the largest opportunities for pharmaceutical
companies to eliminate delays in clinical trials, thereby making it possible to
reduce time to market. With patent time limits and large overheads
meaning that any delays in the development timeline can be disastrous, a good
understanding of how to successfully recruit patients for trials is vital for
any company looking to succeed.
More info >> |
|
 |
News and Press Releases |
 |
Azopharma Product Development Group, Inc
HOLLYWOOD, Fla. – Azopharma Product Development Group, Inc. (“Azopharma”) announced today the addition of innovative state-of-the-art equipment at its formulation and manufacturing division, ApiCross Drug Delivery Technologies in Hollywood, Florida. The most recent acquisition is the MG Futura Capsule Filler which delivers the latest in capsule filling technology. The company has also added a Bausch & Strobel Aseptic Filling Isolator, equipment that is ground-breaking in the powder filling process. These additions support our previously implemented XcelodoseTM powder micro-dosing system. With these technologies, Azopharma is able to provide its clients with all forms of the capsule filling process. The new equipment is part of Azopharma’s recent manufacturing expansion which includes 17 new manufacturing suites for GMP, cytotoxic and aseptic products...
More info >> |
|
 |
